Mycophenolate for Pulmonary Sarcoidosis

Exclusion Criteria

• •1. Previous history of an adverse reaction to mycophenolate.
• •2. Current use of another immunosuppressive medication.
• •3. History of active hepatitis or another significant liver disease with the exception of proven or presumed sarcoidosis of the liver.
• •4. Previous history of skin cancer
• •5. Active peptic ulcer disease
• •6. Pregnant and/ or lactating female
• •7. Serum creatinine \> 2.0 mg/dl
• •8. Serum bilirubin \> 3.0 mg/dl
• •9. WBC \< 4,000/cu mm3
• •10. Has demonstrated non-compliance in the past
• •11. Current alcohol or drug abuse
• •12. Evidence of significant sarcoidosis in extrapulmonary organs that requires therapy such that the mycophenolate doses could not be tapered if the pulmonary sarcoidosis was stable or improved.
• •13. History of previous severe digestive system disease
• •14. Patients taking azathioprine
• •15. Patients taking cholestyramine or other drugs that affect enterohepatic recirculation
• •16. Patients with Lesch-Nyhan or Kelley-Seegmiller syndrome
• •17. Patients be willing not to receive live vaccines during the study
• •18. Patients with phenylketonuria
• •19. Patients with elevated serum transaminases or total bilirubin at baseline